Latest France News

Apollo Minerals welcomes a $2.8 million investment from Tribeca Investment Partners, marking a significant vote of confidence in its Couflens tungsten-gold project in southern France. This capital injection follows a recent $6.5 million raise and aims to accelerate exploration and development activities.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

Little Green Pharma Ltd is set to acquire Cannatrek Ltd in a transformative merger that will create one of the largest vertically integrated medicinal cannabis companies globally, with pro-forma FY25 revenue exceeding AUD 112 million.

Atlas Arteria confirms the extension of France’s temporary supplemental tax into 2026 but maintains its 40 cents per share distribution guidance, signalling confidence amid regulatory shifts.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

Apollo Minerals has secured a five-year reinstatement of its Couflens exploration permit in France, reviving prospects at the historic Salau tungsten mine alongside promising gold mineralisation. The company also advances exploration in Gabon and Serbia while raising A$6.55 million to fund its growth.

Cobalt Blue Holdings has enhanced the financial outlook for its Kwinana Cobalt Refinery project, secured a $5.3 million capital raise, and advanced key environmental and feedstock initiatives amid a tightening cobalt market.

Apollo Minerals has raised $6.5 million through a share placement to advance its Couflens High Grade Tungsten Gold Project in southern France, backed strongly by existing investors and company directors.

Atlas Arteria reported a 9.5% increase in toll revenue for Q4 2025, driven by steady traffic growth and strategic toll hikes across its global toll road portfolio.

Medical Developments International has posted positive operating cashflow for the first half of FY26, driven by robust growth in its flagship product Penthrox across Australia and Europe, alongside progress in paediatric approvals.

Little Green Pharma reports record quarterly revenue and announces a transformative merger with Cannatrek, creating a leading vertically integrated medicinal cannabis group with strong European growth prospects.

Brazilian Rare Earths Limited (BRE) reports a robust scoping study for its Amargosa Bauxite-Gallium Project, alongside a strategic heavy rare earths partnership and a strong cash position to accelerate development.